Biotechnology company The Rigvir Group made a strategic decision on its own initiative, temporarily suspend the distribution of Rigvir medicines in Latvia, while maintaining the existing registration. Such decision is a logical and economically viable step that allows investment and administrative resources to be focused on the implementation of a coordinated research plan for the centralized registration in EU.